Last reviewed · How we verify
Saroglitazar magnesium
At a glance
| Generic name | Saroglitazar magnesium |
|---|---|
| Also known as | not any |
| Sponsor | Zydus Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (PHASE3)
- Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (PHASE3)
- Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (PHASE1)
- Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PHASE3)
- Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII) (PHASE2)
- Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease (PHASE1)
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis (PHASE2)
- Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saroglitazar magnesium CI brief — competitive landscape report
- Saroglitazar magnesium updates RSS · CI watch RSS
- Zydus Therapeutics Inc. portfolio CI